Zhejiang Starry Pharm Co Ltd - Asset Resilience Ratio
Zhejiang Starry Pharm Co Ltd (603520) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Zhejiang Starry Pharm Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Zhejiang Starry Pharm Co Ltd's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Zhejiang Starry Pharm Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Starry Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603520 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥23.15K | 0.0% |
| Total Liquid Assets | CN¥23.15K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Starry Pharm Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Starry Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Starry Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Zhejiang Starry Pharm Co Ltd (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Starry Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | CN¥23.15K ≈ $3.39K |
CN¥5.52 Billion ≈ $807.23 Million |
-0.02pp |
| 2022-12-31 | 0.02% | CN¥876.69K ≈ $128.29K |
CN¥5.30 Billion ≈ $775.88 Million |
-1.42pp |
| 2021-12-31 | 1.43% | CN¥70.16 Million ≈ $10.27 Million |
CN¥4.90 Billion ≈ $716.35 Million |
-1.53pp |
| 2020-12-31 | 2.97% | CN¥130.76 Million ≈ $19.13 Million |
CN¥4.41 Billion ≈ $644.79 Million |
+2.47pp |
| 2017-12-31 | 0.50% | CN¥10.00 Million ≈ $1.46 Million |
CN¥2.01 Billion ≈ $294.62 Million |
-3.20pp |
| 2016-12-31 | 3.70% | CN¥70.00 Million ≈ $10.24 Million |
CN¥1.89 Billion ≈ $277.08 Million |
-- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more